<DOC>
	<DOCNO>NCT02536183</DOCNO>
	<brief_summary>This study look determine maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) lyso-thermosensitive liposomal doxorubicin ( LTLD ) administer combination MR-HIFU child relapsed/refractory solid tumor , may include limited rhabdomyosarcoma soft tissue sarcoma , Ewing 's sarcoma family tumor , osteosarcoma , neuroblastoma , Wilms ' tumor , hepatic tumor , germ cell tumor .</brief_summary>
	<brief_title>A Phase I Study Lyso-thermosensitive Liposomal Doxorubicin MR-HIFU Pediatric Refractory Solid Tumors</brief_title>
	<detailed_description>This phase 1 trial LTLD MR-HIFU induce heat child young adult relapsed/refractory solid tumor . Part A trial traditional dose escalation study determine pediatric MTD/RP2D LTLD combine MR-HIFU ablation allow release doxorubicin ablation zone peri-ablation margin . Part B trial combine LTLD MTD/RP2D MR-HIFU induce mild hyperthermia ( MHT ) expand cohort .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Part A : ≤21 year age Part B : ≤ 30 year age . Histologically confirm malignant solid tumor . Patient must least one tumor locate area accessible HIFU , define target lesion ( ) . Radiographically evaluable measurable solid tumor target lesion ( ) . Malignant tumor relapse refractory potentially curative treatment option available . Must complete appropriate washout period prior therapy . Karnofsky Lansky performance level ≥ 50 % . Must appropriate hematologic , hepatic renal function . Adequate cardiac function ejection fraction &gt; 50 % Clinically significant unrelated systemic illness . Patients pregnant breastfeeding . Target lesion pulmonary primary tumor metastasis . Implant prosthesis scar tissue within path HIFU beam . Target lesion &lt; 1 cm nerve plexus , spinal canal , bowel . Lesion skull . Inability undergo MRI and/or contraindication MRI . Inability tolerate stationary position HIFU . Previous history hypersensitivity doxorubicin liposomal formulation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>relapse pediatric solid tumor</keyword>
	<keyword>high intensity focus ultrasound</keyword>
	<keyword>Lyso-thermosensitive liposomal doxorubicin</keyword>
	<keyword>ThermoDox</keyword>
	<keyword>relapse sarcoma</keyword>
	<keyword>Ewing Sarcoma family tumor</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Wilms Tumor</keyword>
	<keyword>Hepatic Tumor</keyword>
	<keyword>Germ Cell Tumors</keyword>
</DOC>